医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Foo.log Inc. Releases U.S. Localized Version of First Image-Recognition-Assisted Food Recording App for iOS/Android

2015年11月12日 AM01:00
このエントリーをはてなブックマークに追加


 

TOKYO

Foo.log Inc. announced that their photo-based food recording app to visualize eating habits, FoodLog : Calorie Counter, is now available in English as well as is equipped with a U.S. food database. FoodLog allows users to use an image-assisted recording where names of foods in a photo are suggested by image search through a personalized database. The app has been downloaded 78,357 times in Japan in two years.

A food image recognition engine suggests candidates of food descriptions so that a user can select correct one instead of typing its name. The engine, which was developed by Prof. Aizawa and his group in the university of Tokyo, searches through the user’s personal record to produce a list of candidates, thus, the system is fully personalized and it will become wiser as the number of record increases. Free text input is also available if the initial search fails.

FoodLog shows daily intake of calorie and summarizes monthly and yearly average along with photo tiles of dishes. “Keeping record must be pleasure,” said Masanori Kubota, operating officer of foo.log Inc. “You will find the picture tiles themselves are beautiful and valuable because they made you healthy.”

FoodLog is available world-wide on Apple’s App Store and Google Play for free. Please visit app.foodlog.jp for more FoodLog and company information, including videos and screenshots of the app.

Foo.log Inc., based in Tokyo, Japan, was formed in 2005 by Makoto Ogawa to offer ICT services in health care field based on an image analysis technology specialized in food.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151111005022/en/

CONTACT

foo.log Inc.
Msanori Kubota, 81-3-3813-7170
info@foo-log.co.jp

同じカテゴリーの記事 

  • Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D
  • Takeda公布2023财年全年业绩和2024财年展望,确认对后期研发管线开发和提高核心营业利润率的承诺
  • Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
  • AMLにおける寛解期に残存するFLT3-ITD変異と移植後の転帰との間に重要な関連があることが研究によって判明
  • 研究表明AML缓解期残留FLT3-ITD突变与移植后结果之间存在重要联系